Neurocrine Biosciences (LTS:0K6R) Research & Development: $1,049 Mil (TTM As of Mar. 2026)


LTS:0K6R Neurocrine Biosciences Inc LTS:0K6R
96 GF Score
Price $168.33
GF Value $185.19
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Research & Development?

Neurocrine Biosciences LTS:0K6R +0.13% 96 Research & Development is $1,049 Mil as of Mar. 2026. GuruFocus rates LTS:0K6R with a GF Score™ of 96/100 and a GF Value™ of $185.19 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Neurocrine Biosciences's Research & Development for the three months ended in Mar. 2026 was $296 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1,049 Mil.

Neurocrine Biosciences  (LTS:0K6R) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Neurocrine Biosciences Research & Development Related Terms

Neurocrine Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Research & Development Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 328.10 463.80 565.00 731.10 1,015.70

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 263.20 244.30 250.00 258.20 296.20
LTS:0K6R
96GF Score
Neurocrine Biosciences Inc LTS:0K6R
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,049 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1,049 Mil mean?
Neurocrine Biosciences (LTS:0K6R) has a Research & Development of $1,049 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Research & Development too high?
Neurocrine Biosciences' current Research & Development is $1,049 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Research & Development compare to VTRS and ELAN?
Neurocrine Biosciences' Research & Development of $1,049 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Research & Development is $1,049 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $185.19, compared to a current price of $168.33 — trading 9.1% below its estimated fair value. The current Research & Development is $1,049 Mil. Neurocrine Biosciences' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Research & Development is $1,049 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of $168.33 is trading 9.1% below its estimated GF Value™ of $185.19. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for LTS:0K6R:

  • Research & Development: $1,049 Mil
  • GF Value™: $185.19 vs. price of $168.33 (9.1% below fair value)
  • GF Score™: 96/100 with 6 warning signs

No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
96GF Score

Get the complete analysis for LTS:0K6R

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$168.33
Price
$185.19
GF Value